Initially, we tested protein synthesis and MCL-1 non-specific inhibitor homoharringtonine [32, 66], with the benefit of its clinical use to treat chronic myeloid leukemia with only minor side effects [33]. The gene discussed is MCL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.